Show simple item record

dc.contributor.authorPeacock, Andrew J
dc.contributor.authorLing, Yi
dc.contributor.authorJohnson, Martin K
dc.contributor.authorKiely, David G
dc.contributor.authorCondliffe, Robin
dc.contributor.authorElliot, Charlie A
dc.contributor.authorGibbs, J Simon R
dc.contributor.authorHoward, Luke S
dc.contributor.authorPepke-Zaba, Joanna
dc.contributor.authorSheares, Karen K K
dc.contributor.authorCorris, Paul A
dc.contributor.authorFisher, Andrew J
dc.contributor.authorLordan, James L
dc.contributor.authorGaine, Sean
dc.contributor.authorCoghlan, J Gerry
dc.contributor.authorWort, S John
dc.contributor.authorGatzoulis, Michael A
dc.date.accessioned2021-08-12T15:54:36Z
dc.date.available2021-08-12T15:54:36Z
dc.date.issued2020-03-30
dc.identifier.issn2045-8932
dc.identifier.pmid32284847
dc.identifier.doi10.1177/2045894020914851
dc.identifier.urihttp://hdl.handle.net/10147/630047
dc.description.abstractPatients classified as idiopathic pulmonary arterial hypertension (defined as Group 1 on European Respiratory Society (ERS)/European Cardiac Society (ESC) criteria) may have evidence of minor co-existing lung disease on thoracic computed tomography. We hypothesised that these idiopathic pulmonary arterial hypertension patients (IPAH lung disease ) are a separate subgroup of idiopathic pulmonary arterial hypertension with different phenotype and outcome compared with idiopathic pulmonary arterial hypertension patients without co-existing lung disease (IPAH no lung disease ). Patients with 'IPAH lung disease ' have been eligible for all clinical trials of Group 1 patients because they have normal clinical examination and normal spirometry but we wondered whether they responded to treatment and had similar survival to patients with 'IPAH no lung disease '. We described the outcome of the cohort of patients with 'IPAH no lung disease ' in a previous paper. Here, we have compared incident 'IPAH lung disease ' patients with 'IPAH no lung disease ' patients diagnosed concurrently in all eight Pulmonary Hypertension centres in the UK and Ireland between 2001-2009. Compared with 'IPAH no lung disease ' (n = 355), 'IPAH lung disease ' patients (n = 137) were older, less obese, predominantly male, more likely to be current/ex-smokers and had lower six-minute walk distance, lower % predicted diffusion capacity for carbon monoxide, lower mean pulmonary arterial pressure and lower pulmonary vascular resistance index. After three months of pulmonary hypertension-targeted treatment, six-minute walk distance improved equally in 'IPAH lung disease ' and 'IPAH no lung disease '. However, survival of 'IPAH lung disease ' was lower than 'IPAH no lung disease ' (one year survival: 72% compared with 93%). This survival was significantly worse in 'IPAH lung disease ' even after adjusting for age, gender, smoking history, comorbidities and haemodynamics. 'IPAH lung disease ' patients had similar short-term improvement in six-minute walk distance with anti-pulmonary arterial hypertension therapy but worse survival compared with 'IPAH no lung disease ' patients. This suggests that 'IPAH lung disease ' are a separate phenotype and should not be lumped with 'IPAH no lung disease ' in clinical trials of Group 1 pulmonary arterial hypertension.en_US
dc.language.isoenen_US
dc.rights© The Author(s) 2020.
dc.subjectidiopathic pulmonary arterial hypertension (IPAH)en_US
dc.subjectLUNG DISEASEen_US
dc.subjectSurvivalen_US
dc.subjecttreatment responseen_US
dc.titleIdiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?en_US
dc.typeArticleen_US
dc.identifier.journalPulmonary circulationen_US
dc.description.peer-reviewpeer-reviewen_US
dc.source.journaltitlePulmonary circulation
dc.source.volume10
dc.source.issue1
dc.source.beginpage2045894020914851
dc.source.endpage
refterms.dateFOA2021-08-12T15:54:37Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
2045894020914851.pdf
Size:
219.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record